BPTF bromodomain (2796-2907 aa) (GST-tagged), Human recombinant protein
BPTF bromodomain (2796-2907 aa) (GST-tagged), Human recombinant
|Calculated MW||40.1 kDa (2796-2907 aa + NT GST Tag)|
|Other Names||Bromodomain PHD Finger Transcription Factor|
|Storage||-80°C; 50 mM Tris, pH 7.5, containing 500 mM sodium chloride, 5 mM β-mercaptoethanol and 5% glycerol.|
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abgent to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
The acetylation of histone lysine residues plays a crucial role in the epigenetic regulation of gene transcription. A bromodomain is a protein domain that recognizes acetylated lysine residues such as those on the N-terminal tails of histones. This recognition is often a prerequisite for protein-histone association and chromatin remodeling. These domains function in the linking of protein complexes to acetylated nucleosomes, thereby controlling chromatin structure and gene expression. Thus, bromodomains serve as “readers” of histone acetylation marks regulating the transcription of target promoters. BPTF is the largest component of the NURF chromatin remodeling complex. It includes adjacent PHD and bromodomains which recognize trimethylation of H3K4 or acetylation of lysines in histone 4, respectively. BPTF is an essential regulator of gene expression in early mouse embryos, and its knock-out is embryonic lethal. Duplication of the BPTF gene has been suggested to increase proliferation of cultured cancer cells, and aberrant BPTF copy numbers were found in 42% of the “NCI-60” panel of 60 human cancer cell lines. This protein product contains the bromodomain of BPTF.
Jones M.H.,et al.Genomics 63:35-39(2000).
Zody M.C.,et al.Nature 440:1045-1049(2006).
Bowser R.,et al.Dev. Neurosci. 17:20-37(1995).
Barak O.,et al.EMBO J. 22:6089-6100(2003).
Mu X.,et al.Exp. Neurol. 146:17-24(1997).
If you have used an Abgent product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at firstname.lastname@example.org.